Study of Cyclodextrin (SBECD) and Voriconazole Blood Concentrations During Continuous Dialysis
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This study's primary objective is to determine if continuous renal replacement therapy (CRRT)
can adequately remove the sulfobutylether-ß-cyclodextrin sodium (SBECD) vehicle from the
blood so that intravenous voriconazole can be utilized in critically ill patients with renal
dysfunction requiring dialysis. Secondarily, the pharmacokinetics of intravenous voriconazole
and its metabolite (UK121-265) and adverse effects of SBECD accumulation will also be
evaluated. The study hypothesis is that CRRT is effective at removing SBECD and allows
patients to receive intravenous voriconazole without the concern of SBECD accumulation.